Overcoming adaptive therapy resistance in AML by targeting immune response pathways
Katelyn Melgar(Cincinnati Children's Hospital Medical Center), Daniel T. Starczynowski(Cincinnati Children's Hospital Medical Center), Kelli M. Wilson(Johns Hopkins University), Craig J. Thomas(National Institutes of Health), Mark Wunderlich(Cincinnati Children's Hospital Medical Center), Kwangmin Choi(Cincinnati Children's Hospital Medical Center), Ross L. Levine(Memorial Sloan Kettering Cancer Center), Kathleen Hueneman(Cincinnati Children's Hospital Medical Center), Lyndsey Bolanos(Cincinnati Children's Hospital Medical Center), Jan Abendroth(Virginia Mason Bainbridge Island Medical Center), Patrick Sutter(National Institutes of Health), Eric O’Brien(Cincinnati Children's Hospital Medical Center), Gregory J. Tawa(National Institutes of Health), Christopher Famulare(Memorial Sloan Kettering Cancer Center), John P. Perentesis(Cincinnati Children's Hospital Medical Center), LaQuita M. Jones(Virginia Mason Bainbridge Island Medical Center), Donald L. Lorimer(Virginia Mason Bainbridge Island Medical Center), Jian-kang Jiang(National Institutes of Health), Xiaohu Zhang(National Institutes of Health), Amy Wang(National Institutes of Health), Xin Xu(National Institutes of Health), Morgan M. Walker(National Institutes of Health), James C. Mulloy(Cincinnati Children's Hospital Medical Center), Scott B. Hoyt(National Institutes of Health), Ellin Berman(Memorial Sloan Kettering Cancer Center)
Cited by 88
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k